The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
Erleada is a successor to J&J’s Zytiga (abiraterone), which has gone off patent in the US and succumbing to generic competition – sales of the blockbuster were down nearly 60% in Q2 in the US ...
The CAPItello-281 study evaluated the combination of Truqap, J&J’s JNJ Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone ...
It was designed as an alternative abiraterone acetate formulation with clear benefits over branded Zytiga tablets. TAVT-45 granules are rapidly reconstituted in water or juice and easily consumed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback